No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Newron Pharmaceuticals SpA is a biopharmaceutical enterprise headquartered in Bresso, Milano, with a dedicated team of 24 full-time employees. The company's core mission is the discovery and advancement of innovative pharmaceutical products, particularly focusing on new therapies for Central Nervous System (CNS) disorders and pain management. Among its leading candidates, safinamide is currently undergoing Phase III clinical trials for the treatment of Parkinson's disease. Additionally, ralfinamide is being developed as a potential therapy for neuropathic pain. The firm's pipeline further includes a range of projects at various preclinical and clinical development stages, such as HF0220 for neuroprotection, NW-3509 for schizophrenia, and pruvanserin and sarizotan for other CNS conditions.
www.newron.comNo one on the platform currently holds NP5.DE.
No tracked institution reports a position in NP5.DE as of their last filing.
No one on the platform has traded NP5.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -62.8% | 29.5% | ||||
| Profit Margin % | -69.7% | -152.7% | -209.0% | |||
| Free Cash Flow Margin % | 170.0% | -71.5% | -172.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10M | -48.7% | $-1.48 | $-2.95–$-0.16 | — | 1 |
| 2027 | $43M | +317.3% | $0.13 | $0.01–$0.26 | — | 1 |
| 2028 | $121M | +180.3% | $-2.24 | $-4.46–$-0.24 | — | 1 |
| 2029 | $164M | +35.6% | $4.14 | $0.44–$8.25 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-03-24 | $-0.56 | $-0.66 | -17.9% |
| 2025-06-30 | $-0.41 | $-0.00 | +99.1% |
| $361M |
| — |
| GME.DEGeratherm Medical AG | $2.45 | +0.00% | $13M | — |
| HPHA.DEHeidelberg Pharma AG | $2.51 | +4.58% | $117M | — |
Source: Financial Modeling Prep · peers by sector/industry